NPHC.OTC.PinkNutra Pharma CORP
10-Q: Nutra Pharma Reports Q3 Loss Amidst Debt & SEC Penalties
Sentiment:
Quarterly Report
Nutra Pharma Corp. reported a significant net loss for the nine months ended September 30, 2023, alongside substantial debt and ongoing legal challenges, raising going concern doubts.
Delay expectedThe process for regulatory approval of Nyloxin in Canada was delayed due to lack of funding and the COVID crisis, with re-engagement expected in 2026.Human clinical studies aimed at comparing Nyloxin Extra Strength to replace prescription pain relievers have no timeline until adequate financing is available.The initiation of Phase I/II trials for RPI78M in the treatment of Pediatric Multiple Sclerosis is a goal for 2026, indicating a future-dated plan for drug development.
Capital raiseThe company continues to rely principally on debt and equity funding, and will require additional financing to execute its operating plan and continue as a going concern.During the nine months ended September 30, 2023, the company raised $36,500 through the issuance of convertible notes and $182,200 through the issuance of promissory notes.Management expects to utilize proceeds from these funds and additional capital to manufacture products and reduce debt.The company estimates requiring approximately $600,000 to fund existing operations over the next twelve months, and may need to raise additional equity capital, which could result in substantial dilution.The company may also seek additional loans from its officers and directors.
Worse than expectedThe company reported a net loss of $1,150,292 for the nine months ended September 30, 2023, a significant deterioration from a net income of $4,944,891 in the prior year period.The change in fair value of convertible notes and derivatives resulted in a loss of $116,850 for the nine months ended September 30, 2023, compared to a gain of $6,569,581 in the prior year, directly contributing to the net loss.Bad debt expense from a related party increased to $105,465 for the nine months ended September 30, 2023, from $0 in the prior year, negatively impacting profitability.The company continues to operate with a substantial accumulated deficit, working capital deficit, and stockholders deficit, indicating ongoing financial instability.
Summary
- Nutra Pharma Corp. reported a net loss of $1,150,292 for the nine months ended September 30, 2023, a significant decline from a net income of $4,944,891 in the prior year period.
- Total net sales increased by 107.3% to $459,738 for the nine months ended September 30, 2023, compared to $221,780 in the same period of 2022.
- Gross profit margin improved to 65.85% for the nine months ended September 30, 2023, up from 47.6% in the prior year, primarily due to lower manufacturing costs.
- The company has an accumulated deficit of $74,702,410, a working capital deficit of $13,586,792, and a stockholders deficit of $13,525,244 as of September 30, 2023.
- A final judgment in the SEC lawsuit issued in July 2024 ordered the company to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty.
- A settlement was reached in the CSA 8411, LLC lawsuit for $125,000, with an initial payment of $35,000 made on May 19, 2025, and subsequent monthly payments.
- Disclosure controls and procedures were deemed not effective as of September 30, 2023, due to material weaknesses in internal control over financial reporting.
- The company continues to rely on debt and equity funding, having raised $36,500 through convertible notes and $182,200 through promissory notes during the nine months ended September 30, 2023.
Sentiment
Score: 2
Explanation: The company faces severe financial distress, including significant net losses, substantial accumulated and working capital deficits, and a going concern warning. While sales increased, the overall financial health is precarious, compounded by legal penalties and reliance on dilutive financing. The positive sales growth is overshadowed by the magnitude of the financial challenges and governance issues.
Positives
- Net sales to unrelated customers increased by 137.27% to $158,532 for the nine months ended September 30, 2023, driven by higher sales of Nyloxin and Pet Pain-Away.
- Net sales to a related party increased by 94.37% to $301,206 for the nine months ended September 30, 2023, reflecting stronger demand for existing products.
- Gross profit margin significantly improved to 65.85% for the nine months ended September 30, 2023, compared to 47.6% in the prior year, mainly due to lower manufacturing costs.
- Selling, general and administrative expenses decreased by 4.8% to $944,008 for the nine months ended September 30, 2023, primarily due to lower professional fees.
- Loss from operations improved to $(746,757) for the nine months ended September 30, 2023, compared to $(886,031) in the prior year period.
- Interest expense, including related party interest, decreased by 46.37% to $317,929 for the nine months ended September 30, 2023.
- Loss on settlement of debts decreased significantly by 98.8% to $1,850 for the nine months ended September 30, 2023, due to fewer debt settlements.
Negatives
- The company reported a net loss of $1,150,292 for the nine months ended September 30, 2023, a substantial reversal from a net income of $4,944,891 in the comparable prior year period.
- An accumulated deficit of $74,702,410 as of September 30, 2023, indicates a history of significant losses.
- A working capital deficit of $13,586,792 and a stockholders deficit of $13,525,244 as of September 30, 2023, highlight severe liquidity and solvency issues.
- The company has a significant amount of indebtedness in default.
- Bad debt expense from a related party was $105,465 for the nine months ended September 30, 2023, compared to $0 in the prior year.
- The change in fair value of convertible notes and derivatives resulted in a loss of $116,850 for the nine months ended September 30, 2023, a negative swing from a gain of $6,569,581 in the prior year.
- The company had no cash or cash equivalents balances as of September 30, 2023, and December 31, 2022.
- Disclosure controls and procedures were not effective as of September 30, 2023, due to material weaknesses in internal control over financial reporting.
Risks
- Substantial doubt exists regarding the company's ability to continue as a going concern due to recurring losses, significant indebtedness in default, and working capital/stockholders deficits.
- The company's ability to secure additional financing is uncertain, which is critical for executing its operating plan and continuing as a going concern.
- The common stock is on the OTC Market Groups Expert Market, limiting the ability to raise capital through proprietary broker-deal quotes.
- Future revenues from product sales may be insufficient to cover operating expenses, necessitating additional equity capital which could result in substantial dilution.
- The company faces risks related to successfully developing and commercializing products from its research and development activities.
- Failure to compete effectively in the intensely competitive biotechnology area could negatively impact operations and market position.
- Inability to successfully execute planned partnering and out-licensing of products or technologies could adversely affect future performance.
- The biotechnology industry is prone to substantial and rising litigation, leading to greater costs and unpredictable outcomes.
- Failure to comply with extensive legal/regulatory requirements in the healthcare industry could lead to increased costs, penalties, and business losses.
Future Outlook
The company aims to increase sales and awareness of its products through more aggressive marketing as sales increase. It plans to re-engage in the Canadian regulatory approval process for Nyloxin in 2026 and initiate Phase I/II clinical trials for RPI78M in Pediatric Multiple Sclerosis in 2026, contingent on adequate financing. The company estimates requiring approximately $600,000 to fund existing operations over the next twelve months, excluding research and development costs or clinical study expenses.
Management Comments
- "Our plan is to attempt to secure adequate funding through notes payable until sales of our pain products are adequate to fund our operations."
- "We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form."
- "We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern."
- "Our goal is that with Nyloxin, we can greatly reduce the instances of opiate abuse and overuse of NSAIDS in high risk groups like the US military."
- "We are currently working with consultants to develop trial protocols for a Phase I/II trial for the use of RPI78M in the treatment of Pediatric Multiple Sclerosis. Our goal is to initiate these trials in 2026."
Industry Context
Nutra Pharma operates in the biotechnology and homeopathic pain relief markets. Its focus on non-opioid pain relievers like Nyloxin aligns with broader healthcare trends seeking alternatives to address the opioid crisis and concerns about NSAID overuse. The development of RPI78M for Multiple Sclerosis, particularly with Orphan Status, positions it in a specialized, high-need area within the biologics market, potentially offering a novel oral administration method. However, the company's significant financial distress and reliance on debt funding contrast sharply with the capital-intensive nature of drug development and the competitive landscape of both OTC and pharmaceutical industries.
Comparison to Industry Standards
- The company's accumulated deficit of over $74 million and persistent working capital and stockholders deficits are significantly below industry standards for a healthy, publicly traded biotechnology company, which typically require substantial capital for R&D and commercialization.
- The reliance on convertible notes and promissory notes, many of which are in default, indicates a struggle to secure traditional, less dilutive financing common in the biotech sector, where venture capital or larger institutional investments are more typical for early-stage drug development.
- The company's common stock being on the OTC Market Groups Expert Market, rather than a major exchange, limits its access to capital and investor visibility compared to industry peers.
- While the increase in net sales is positive, the overall revenue figures remain very low for a company with a drug discovery pipeline, especially when compared to established pharmaceutical or even emerging biotech companies that often report revenues in the millions or billions.
- The significant legal penalties from the SEC lawsuit ($680,235 total) are a substantial burden and reflect corporate governance issues that are atypical and detrimental compared to industry best practices.
- The long timelines for clinical trials (e.g., RPI78M Phase I/II in 2026) are not unusual for drug development, but the explicit mention of 'lack of funding' as a constraint highlights a critical weakness compared to well-funded industry competitors like Biogen (MS treatments) or Pfizer (pain management) that have robust R&D budgets.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Disclosure Controls and Procedures Effectiveness | Disclosure controls and procedures were not effective as of September 30, 2023, due to material weaknesses in internal control over financial reporting. | 2023-09-30 | Indicates significant deficiencies in the company's ability to record, process, summarize, and report financial information, posing a high risk to financial reporting integrity and investor confidence. |
Legal Proceedings
- **CSA 8411, LLC v. Nutra Pharma Corp. (Case No. CACE 18-023150)**: A lawsuit filed on October 12, 2018, to recover $100,000 allegedly owed under an amended promissory note. A settlement agreement was reached on May 19, 2025, for $125,000, with an initial payment of $35,000 and nine subsequent monthly payments of $10,000. A gain on settlement of $53,526 is expected upon full satisfaction of payment terms. A default in payments could lead to a consent judgment of $400,000.
- **Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus (Case No. 2:18-cv-05459)**: A lawsuit filed on September 28, 2018, alleging fraud, false and misleading statements, unregistered private placements, and manipulative trades. A final judgment issued in July 2024 ordered the company to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty. The company had accrued a total legal settlement amount of $680,235 as of September 30, 2023.
Related Party Transactions
- The company acts as a product formulator and contract manufacturer for Avini Health, a company owned and controlled by Rik Deitsch, the company's former CEO and current chief scientific officer.
- Net sales to a related party (Avini Health) were $301,206 for the nine months ended September 30, 2023, compared to $154,966 for the same period in 2022.
- Bad debt expense of $105,465 was recorded for receivables from companies controlled by the former CEO for the nine months ended September 30, 2023.
- The net balance due to Rik Deitsch (former CEO) and his controlled companies was $579,610 as of September 30, 2023, accruing interest at 4%.
- Accrued payroll due to officers totaled $1,333,693 as of September 30, 2023.
- Accrued interest to related parties was $163,771 as of September 30, 2023.
- A sublease agreement with Avini Health for monthly rent of $5,000 was terminated on August 31, 2023.
- These transactions were not conducted on an arms-length basis and may differ from terms negotiated with unrelated third parties.
Stakeholder Impact
- **Shareholders**: Face significant dilution risk from potential future equity raises and conversions of existing convertible debt. The substantial accumulated deficit and going concern warning indicate a high risk of further value erosion. The stock being on the OTC Expert Market limits liquidity and visibility.
- **Creditors**: Many debts are in default, indicating high risk of non-payment or further restructuring. Legal settlements and penalties add to the financial burden, potentially impacting the ability to repay other creditors.
- **Employees**: The company's precarious financial position and reliance on external funding create uncertainty regarding job security and long-term stability.
- **Customers**: Continued product availability may be impacted by the company's financial health and ability to fund manufacturing and marketing efforts.
- **Regulatory Authorities**: The SEC lawsuit and subsequent penalties highlight past non-compliance with securities laws, which could lead to increased scrutiny and operational restrictions.
Next Steps
- Secure additional financing to fund operations and address liquidity issues.
- Increase sales and awareness of existing products through more aggressive marketing.
- Re-engage in the process for regulatory approval of Nyloxin in Canada by 2026.
- Initiate Phase I/II clinical trials for RPI78M in Pediatric Multiple Sclerosis by 2026, contingent on securing adequate financing.
- Continue to negotiate settlements for outstanding debts and legal proceedings.
- Address material weaknesses in internal control over financial reporting to improve disclosure controls and procedures.
Key Dates
| Date | Description |
|---|---|
| 2000-02-01 | Nutra Pharma Corp. incorporated under the laws of California. |
| 2009-10-01 | Launched its first consumer product, Cobroxin. |
| 2010-05-01 | Launched its second consumer product, Nyloxin. |
| 2011-08-02 | Entered into a settlement agreement with Liquid Packaging Resources, Inc. (LPR). |
| 2011-12-01 | Began marketing Nyloxin and Nyloxin Extra Strength at www.nyloxin.com. |
| 2012-06-01 | LPR sold the note to Southridge Partners, LLP for $281,772. |
| 2012-12-01 | Announced the availability of Nyloxin Military Strength. |
| 2013-03-25 | Announced the publication of its patent and trademark for Nyloxin in India. |
| 2013-06-01 | Announced the launch of Pet PainAway. |
| 2013-08-01 | Debt of $281,772 reverted back to LPR. |
| 2013-10-01 | Announced the launch of Equine Nyloxin (rebranded as Equine Pain-Away). |
| 2014-12-01 | Pet PainAway initial product run completed and launched through Lumaxa Distributors. |
| 2015-05-14 | Engaged Natures Clinic for regulatory approval of Nyloxin in Canada. |
| 2015-07-01 | Signed a consulting services agreement for five years. |
| 2015-10-01 | Signed a consulting agreement for one year. |
| 2016-04-01 | Issued a promissory note to an unrelated third party in the amount of $10,000. |
| 2016-05-01 | Issued a promissory note to an unrelated third party in the amount of $75,000. |
| 2016-06-01 | Issued a promissory note to an unrelated third party in the amount of $50,000. |
| 2016-08-01 | Issued two Promissory Notes for a total of $200,000 to a company owned by a former director. |
| 2016-09-26 | Issued a promissory note to an unrelated third party in the amount of $75,000. |
| 2016-10-01 | Issued a promissory note to an unrelated third party in the amount of $50,000. |
| 2016-11-01 | Announced license agreement with DEG Productions for marketing and distribution of Pet PainAway globally. |
| 2016-12-01 | DEG Productions began airing commercials for Pet PainAway. |
| 2016-12-31 | Repaid the principal balance of a $200,000 loan from a director in full. |
| 2017-04-01 | Accepted offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. |
| 2017-05-01 | Issued a Convertible Debenture in the amount of $64,000 to an unrelated third party. |
| 2017-06-01 | Announced the creation of Luxury Feet. |
| 2017-06-01 | Issued a promissory note to an unrelated third party in the amount of $12,500. |
| 2017-07-01 | Received a loan for a total of $200,000 from an unrelated third party. |
| 2017-07-01 | Issued a promissory note to an unrelated third party in the amount of $50,000. |
| 2017-08-01 | ReceptoPharm renewed its operating lease agreement for five years. |
| 2017-10-01 | Issued a promissory note to an unrelated third party in the amount of $60,000 with a conversion option. |
| 2017-11-01 | Issued a promissory note to an unrelated third party in the amount of $120,000. |
| 2017-11-01 | Issued a promissory note to an unrelated third party in the amount of $18,000. |
| 2018-02-01 | Nyloxin was added to the Federal Supply Schedule but subsequently removed. |
| 2018-06-01 | Loan of $200,000 (July 2017) settled with two unrelated third parties for $130,401 and $40,000. |
| 2018-07-01 | Issued a convertible debenture in the amount of $50,000 to an unrelated third party. |
| 2018-08-01 | Issued a convertible debenture in the amount of $20,000 to an unrelated third party. |
| 2018-09-28 | The United States Securities and Exchange Commission (SEC) filed a lawsuit against the Company, Mr. Deitsch, and Mr. McManus. |
| 2018-10-12 | CSA 8411, LLC filed a lawsuit against the Company to recover $100,000. |
| 2018-11-01 | The Company filed its Answer and Affirmative Defenses to the CSA 8411, LLC Complaint. |
| 2019-01-01 | Issued a convertible debenture in the amount of $75,900 to an unrelated third party. |
| 2019-01-31 | Remaining principal balance of $60,000 and accrued interest of $15,900 (from Sept 2016 note) restated as a Convertible Note. |
| 2019-02-01 | Issued a convertible promissory note to an unrelated third party for up to $1,000,000. |
| 2019-05-29 | The SEC filed a First Amended Complaint. |
| 2019-06-01 | Issued a convertible promissory note to an unrelated third party for $240,000. |
| 2019-06-21 | Mediation for the CSA 8411, LLC lawsuit was unsuccessful. |
| 2019-10-01 | Equine Nyloxin was rebranded as Equine Pain-Away and officially rolled into the market. |
| 2020-02-01 | Took back the marketing of Pet Pain-Away. |
| 2020-03-01 | $50,000 of the $120,000 note (Nov 2017) was settled for 125,000,000 shares. |
| 2020-03-31 | The Court entered an Order granting in part and denying in part the various motions to dismiss in the SEC lawsuit. |
| 2020-04-01 | Executed standard loan documents for securing a loan from the SBA under its Economic Injury Disaster Loan assistance program (EIDL Loan). |
| 2020-08-01 | Convertible promissory notes of $38,500 were amended. |
| 2020-10-01 | Issued a Convertible Debenture in the amount of $250,000 to an unrelated third party. |
| 2020-10-01 | A convertible promissory note of $16,500 was amended. |
| 2020-11-01 | The Note holder assigned $20,000 of the $75,900 convertible note (Jan 2019) to a third party. |
| 2020-11-01 | Granted 71,875,000 warrants in connection with convertible notes. |
| 2021-03-01 | Launched Luxury Feet. |
| 2021-03-01 | The remaining balance of the promissory note of $30,000 (originally issued in September 2018) was sold to an unrelated third party in the form of a convertible note. |
| 2021-03-31 | The portion of settlement of $130,401 (June 2018) was repaid in full. |
| 2021-04-09 | Plaintiff filed a Motion for Partial Summary Judgment in the SEC lawsuit. |
| 2021-08-01 | The promissory note of $166,926 was restated in the form of a convertible note. |
| 2021-11-01 | The Board of Directors approved resolutions for the issuance of a total of 9,000,000 shares of Series B Preferred stock to Mr. Deitsch. |
| 2021-11-15 | The Board of Directors authorized an exchange of 3,000,000 shares of Series A Preferred Stock held by Mr. Deitsch for an equal number of Series B Preferred Stock. |
| 2021-12-01 | Granted 246,428,571 warrants in connection with convertible notes. |
| 2022-01-01 | Adopted ASU 2020-06, DebtDebt with Conversion and Other Options (Subtopic 470-20) and Derivatives and HedgingContracts in Entitys Own Equity (Subtopic 815-40). |
| 2022-01-01 | Amended convertible promissory notes of $38,500 to be due in August 2022. |
| 2022-01-01 | Granted 164,285,714 warrants in connection with a convertible note. |
| 2022-02-01 | Issued 20,866,250 shares of common stock to satisfy $16,693 principal balance. |
| 2022-05-01 | The Company sublet a portion of its space to Avini Health. |
| 2022-05-01 | $16,500 of the notes issued in November 2020 were settled through the issuance of common stock. |
| 2022-05-01 | Issued 222,500,000 shares of common stocks in satisfaction of $108,500 of the Notes. |
| 2022-06-01 | Entered a Purchase and Sale of Future Receipts Agreement with a non-related party for $87,000. |
| 2022-06-01 | Repaid a convertible note payable originated in May 2021 in cash for $5,750. |
| 2022-08-01 | Settled a convertible note payable of $17,250 issued in July 2021 for a total repayment of $18,000. |
| 2022-08-01 | The balance of $166,926 was further restated with an original issuance discount of $16,693 in the form of a convertible note. |
| 2022-09-01 | Renewed its consulting agreement with an external consultant for a three-year term. |
| 2022-10-01 | Signed another lease extension, covering the period from January 1, 2023, to December 31, 2025. |
| 2022-10-01 | Received a second loan for $199,000. |
| 2022-11-01 | Settled a convertible note payable of $11,500, originally issued in April 2021, with a cash payment of $12,363. |
| 2022-12-31 | Issued a promissory note of $17,000 to an unrelated third party. |
| 2023-01-01 | Adopted ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326). |
| 2023-02-01 | Issued a $25,000 promissory note to the same party, using the proceeds to fully repay the December 2022 loan. |
| 2023-02-01 | Settled a $1,150 convertible note originated in January 2021 with a cash payment of $1,500. |
| 2023-02-01 | Installment payments for the SBA EIDL Loan commenced. |
| 2023-03-01 | Repaid $5,000 of its outstanding convertible promissory notes of $52,500 originated in September 2021. |
| 2023-06-05 | Entered into a settlement agreement with StemSation to convert notes receivable balances of $264,000 into shares of StemSations common stock. |
| 2023-06-15 | The settlement agreement with StemSation was approved by the Circuit Court. |
| 2023-06-01 | Entered into a Purchase and Sale of Future Receipts Agreement with an unrelated third party for $135,850. |
| 2023-07-01 | Issued a new $32,000 promissory note to the same party, with the proceeds applied to retire the February 2023 note. |
| 2023-07-12 | $33,516 of the $264,000 StemSation settlement was converted into 19,043,425 shares. |
| 2023-08-01 | The July 2023 note was repaid in connection with the issuance of a $34,000 promissory note. |
| 2023-08-23 | Noteholder received 25,000,000 shares of restricted common stock in satisfaction of $12,500 of the Note. |
| 2023-08-24 | $35,200 of the $264,000 StemSation settlement was converted into 20,000,000 shares. |
| 2023-08-31 | The sublease with Avini Health was terminated. |
| 2023-09-30 | End of the quarterly reporting period. |
| 2023-10-01 | Issued convertible promissory notes to unrelated third parties for a total of $97,750. |
| 2023-10-01 | Issued a convertible promissory note to an unrelated third party for $6,613. |
| 2023-10-01 | Purchased multiple convertible notes from StemSation International for a total of $40,750. |
| 2023-11-01 | Received 20,000,000 additional shares of StemSation common stock as the third tranche under the settlement agreement. |
| 2023-11-07 | $35,200 of the $264,000 StemSation settlement was converted into 20,000,000 shares. |
| 2024-01-01 | Issued convertible promissory notes to unrelated third parties for a total of $23,000. |
| 2024-01-01 | Issued convertible promissory notes to unrelated third parties for a total of $105,800. |
| 2024-02-01 | Entered into a second Purchase and Sale of Future Receipts Agreement for $104,400. |
| 2024-02-01 | Issued 35,000,000 restricted shares to a Note holder due to default on repayments of a promissory note. |
| 2024-02-01 | Convertible promissory notes totaling $200,312 were subsequently restated. |
| 2024-03-01 | Sold 10,000,000 shares of StemSation common stock to a third party for $17,600. |
| 2024-03-22 | Announced a settlement in the civil lawsuit brought by the SEC. |
| 2024-04-01 | Issued convertible promissory notes to unrelated third parties for a total of $40,250. |
| 2024-04-01 | Issued convertible promissory notes to unrelated third parties for a total of $31,050. |
| 2024-07-01 | A final judgment was issued in the SEC lawsuit, ordering the defendant to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty. |
| 2024-07-01 | Entered into a one-year Research Services Agreement with StemSation. |
| 2024-10-01 | Entered into a Purchase and Sale of Future Receipts Agreement with a third party for $99,400. |
| 2024-10-31 | The second Purchase and Sale of Future Receipts Agreement (February 2024) was fully repaid. |
| 2024-11-01 | Fully repaid the $199,000 promissory notes that were originally issued in October 2022. |
| 2024-12-01 | Entered into a Purchase and Sale of Future Receipts Agreement with a third party for $68,500. |
| 2024-12-31 | Issued convertible promissory notes to unrelated third parties for a total of $63,250. |
| 2025-01-01 | Issued a convertible promissory note to an unrelated third party for $345,639. |
| 2025-02-01 | The convertible promissory note of $230,000 (restated February 2024) was further restated. |
| 2025-02-01 | Issued two convertible promissory notes to an unrelated third party for a total commitment of up to $855,000. |
| 2025-03-31 | The Research Services Agreement with StemSation was terminated. |
| 2025-04-01 | Issued convertible promissory notes to unrelated third parties for a total of $40,250. |
| 2025-05-01 | Purchased a convertible note from StemSation for $28,750. |
| 2025-05-19 | Entered into a settlement agreement with the counterparty in the CSA 8411, LLC lawsuit for $125,000. |
| 2025-05-19 | An initial payment of $35,000 was made for the CSA 8411, LLC settlement. |
| 2025-06-01 | Payments totaling $30,000 were made for the CSA 8411, LLC settlement. |
| 2025-10-28 | Date of filing of this Quarterly Report on Form 10-Q. |
| 2026-01-01 | Expects to re-engage in the process for regulatory approval of Nyloxin in Canada. |
| 2026-01-01 | Goal to initiate Phase I/II trial for the use of RPI78M in the treatment of Pediatric Multiple Sclerosis. |
Recommendation
strong sellThe company faces severe financial distress, evidenced by a substantial net loss, significant accumulated deficit, and negative working capital and stockholders' equity. The explicit 'going concern' warning, coupled with a high volume of defaulted debt and no cash on hand, indicates an extremely high risk of insolvency. Furthermore, the company has been found liable in an SEC lawsuit, incurring significant penalties, and its disclosure controls were deemed ineffective. While sales have increased, the fundamental financial and governance issues are overwhelming, making the stock a highly speculative and risky investment with a strong likelihood of further value decline and potential delisting or bankruptcy.
Keywords
Biotechnology, Pharmaceuticals, Pain Relief, OTC Products, SEC Filing, 10-Q, Financial Performance, Going Concern, Debt Default, Legal Proceedings, Corporate Governance, Drug Development, Nyloxin, Pet Pain-Away, RPI78M, Orphan Drug Status
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.